Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease

Hong-Mei Yan1☯, Ming-Feng Xia1☯, Yan Wang2, Xin-Xia Chang1, Xiu-Zhong Yao3, Sheng-Xiang Rao3, Meng-Su Zeng3, Yin-Fang Tu4, Ru Feng2, Wei-Ping Jia4, Jun Liu5, Wei Deng6, Jian-Dong Jiang2*, Xin Gao1*

1 Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, 200032, China, 2 Institute of Materia Medica, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing, 100050, China, 3 Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China, 4 Department of Endocrinology and Metabolism, The Sixth People’s Hospital, Shanghai Jiaotong University, Shanghai, 200233, China, 5 Department of Endocrinology and Metabolism, The Fifth People’s Hospital, Fudan University, Shanghai, 200240, China, 6 School of public health, Fudan University, Shanghai, 200032, China

☯ These authors contributed equally to this work.

* happy20061208@126.com (XG); jiang.jdong@163.com (JJ)

Abstract

Objectives
A randomized, parallel controlled, open-label clinical trial was conducted to evaluate the effect of a botanic compound berberine (BBR) on NAFLD.

Methods
A randomized, parallel controlled, open-label clinical trial was conducted in three medical centers (NIH Registration number: NCT00633282). A total of 184 eligible patients with NAFLD were enrolled and randomly received (i) lifestyle intervention (LSI), (ii) LSI plus pioglitazone (PGZ) 15mg qd, and (iii) LSI plus BBR 0.5g tid, respectively, for 16 weeks. Hepatic fat content (HFC), serum glucose and lipid profiles, liver enzymes and serum and urine BBR concentrations were assessed before and after treatment. We also analyzed hepatic BBR content and expression of genes related to glucose and lipid metabolism in an animal model of NAFLD treated with BBR.

Results
As compared with LSI, BBR treatment plus LSI resulted in a significant reduction of HFC (52.7% vs 36.4%, p = 0.008), paralleled with better improvement in body weight, HOMA-IR, and serum lipid profiles (all p < 0.05). BBR was more effective than PGZ 15mg qd in reducing body weight and improving lipid profile. BBR-related adverse events were mild and mainly occurred in digestive system. Serum and urine BBR concentrations were 6.99ng/ml and 79.2ng/ml, respectively, in the BBR-treated subjects. We also analyzed hepatic BBR content and expression of genes related to glucose and lipid metabolism in an animal model of NAFLD treated with BBR.
Conclusion

BBR ameliorates NAFLD and related metabolic disorders. The therapeutic effect of BBR on NAFLD may involve a direct regulation of hepatic lipid metabolism.

Trial Registration

ClinicalTrials.gov NCT00633282
Eligible adults were identified and recruited from unsolicited referrals to the three participating clinical centers from March 2008 to August 2011. Hepatic fat content (HFC) was assessed by a proton magnetic resonance spectroscopy (1H MRS) [16], and patients with a more than 13% HFC were enrolled in the study. Impaired glucose metabolism including IGR or T2DM was defined by fasting plasma glucose (FPG) value ≥ 5.6 mmol/L and/or 2 hour postload plasma glucose (PPG) following a 75-g oral glucose challenge ≥ 7.8 mmol/L. The course of T2DM should be less than 1 year for T2DM patients. Subjects were excluded if they had alcohol consumption ≥ 10 g/d for women and ≥ 20 g/d for men [17], positive for hepatitis B or C, or had other liver diseases. Patients who were treated with the following drugs within 4 weeks before enrollment were also excluded from the study, including hypoglycemic or lipid-regulating (statins, fibrates) drugs, the drugs that may impact hepatic fat content (e.g. silybin, ursodeoxycholic acid, bicyclol, phosphatidylcholine and vitamin E) and Chinese herbs. For safety concern, those with severe metabolic abnormalities and organ dysfunction were excluded, for example, HbA1c > 7.5%, serum triglyceride ≥ 5.0 mmol/L, ALT or AST ≥ 2 times upper limit of normal, serum creatinine i 1.5 mg/dL (133 μmol/L) and blood pressure ≥ 160/100 mmHg in receiving lifestyle therapy and anti-hypertensive drugs. The study was approved by the ethics committee of Zhongshan Hospital, Fudan University and was conducted in accordance with the guidelines of the Declaration of Helsinki, and the Committee was in charge of monitoring the results quarterly to ensure patients’ safety and review of the therapeutic efficacy. Written informed consent was obtained from all patients.

Study Design

Subjects who met all enrollment criteria were randomly assigned to one of the three groups for the 16-weeks clinical trial, Group A- LSI, Group B- LSI plus PGZ (15 mg q.d.) and Group C-LSI plus BBR (0.5 g, t.i.d.). BBR (berberine, Huashi Pharmaceuticals Shanghai, China, Inc.) was administered orally at a dosage of 0.5 g 30 minutes before meal, three times a day (according to the Chinese Pharmacopeia [18]). The computer-generated random allocation sequence was obtained independently by the statistician from School of public health, Fudan University, Shanghai, China. Research investigators randomized participants to one of the three arms. LSI (including dietary modification and exercise) was conducted following the standardized recommendation [19]. The daily dietary before entering the study were comparable among the three groups, and all of the participants were required to take the calorie limited-diet by subtracting 500 kcal from the mean daily calorie intake and achieve more than 150 min per week medium intensity aerobic exercise. The primary outcome was the decrease in HFC detected by 1H MRS; and the secondary outcomes included improvement in body weight, oral glucose tolerance test (OGTT) serum glucose and insulin, HbA1c, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), Homeostatic Model Assessment, Kunes (HOMA-β), lipid profile (TC, TG, HDL-c, LDL-c, ApoA, ApoB, ApoE, Lpa) and liver enzymes (ALT, AST, γ-GT, ALP). Both at the beginning and completion of the treatment, each participant underwent an interview by a trained investigator, an assessment of anthropometric parameters and blood examinations for the evaluation of glucose, lipid profile and liver enzymes. HFC was measured using 1H MRS. The patients were closely followed every 4 weeks throughout the 16-week study, and the follow-up visit was designed mainly for the assessment of safety and tolerability of the study drugs. In case that adverse event was found over the treatment course, the relevant personnel should inform responsible clinical researchers and principal investigator within 24 h. In each of the visits throughout the treatment, we evaluated interim safety related events, adherence, pill counts and collect the participants’ serum. Urine pregnancy tests were performed at each visit for female participants with child-bearing age. The serum and urine
concentrations of BBR and its metabolites were measured by LC-MS/MS as described in detail previously [20].

Measurement of liver fat content using 1H-MRS

LFCs were by 1H-MRS using a 1.5T magnetic resonance (MR) scanner (Siemens Avanto, Erlangen, Germany) equipped for proton spectroscopy acquisitions. Sagittal, coronal, and axial slices covering the whole liver were preliminarily acquired for positioning of the spectroscopy acquisition voxel. A single voxel of 8cm³(2 × 2 × 2 cm) was placed within the right lobe avoiding major vascular structures and subcutaneous fat tissue. The proton spectrum was acquired using the body coil after shimming over the volume of interest by means of a point-resolved spectroscopy (PRESS) sequence with the following parameters: repetition time = 1500 milliseconds, echo time = 135 milliseconds. Signal intensities of water peak at 4.8ppm (Sw) and the fat peak at 1.4ppm (Sf) were measured and hepatic fat percentage was calculated using the formula 100×Sf/(Sf+Sw), as described by our group previously [21].

Animals Study

Thirty six healthy male SD rats (5–6 weeks old) weighing 190–210 gram were obtained from the Animal Development Center, Chinese Academy of Sciences, Shanghai. All rats were given free access to food and water, maintained on a 12/12-h light/dark cycle and received a high-fat diet (32.6% carbohydrate, 51.0% fat, 16.4% protein calories) for 6 weeks to establish the HFD-induced NAFLD model. BBR was purchased from Sigma-Aldrich (MO, USA), and administered at a single dose of 200mg/kg to the HFD-induced rat of NAFLD. The rats were sacrificed by cervical dislocation, and serum and liver tissue samples were collected at 0, 4, 8, 12, 24 and 48h, respectively (n = 6 for each time point), after oral administration of single-dose BBR, which was the most commonly used dose for animal studies [11,12]. All samples were stored at -80°C. Quantitative analysis of BBR and its metabolites in blood and urine were done with the method described [22]. The frozen tissue was used for preparation of mRNA and complementary DNA for use in real-time quantitative polymerase-chain-reaction (PCR) analysis, and the details and the sequences of the primers used in this study are listed in S1 Text; Protein was also extracted from the frozen tissue, and its abundance was quantified through Western Blot Analysis. The antibodies used for immunoblotting included anti-MTTP (Bioworld), anti-Glucokinase (Proteintech), and anti- CPT1α (Proteintech). BBR and its metabolites in the liver tissue were quantified using a shimadzu triple-quadruple MS (LC–MS/MS 8040; Shimadzu Corporation, Kyoto Japan) (S1 Text). The animal study design conformed to the NC3Rs ARRIVE Guideline (S1 ARRIVE Checklist). All experimental procedures involving the use of animals were conducted in conformity with PHS policy and were approved by the Animal Use and Care Committee of Fudan University.

Statistical Analysis

Categorical variables were normalized in frequencies (or percentages) and continuous variables were expressed as means±SD, except for skewed variables, which were presented as the median with the interquartile range given in parentheses. Kolmogorov-Smirnov test was carried out to determine the normality of the continuous variables. The difference between baseline values to that after 16 weeks on treatment with BBR plus LSI were compared with that treated with the LSI or PGZ plus LSI, using the general linear model in order to adjust for baseline value. Given the fact that there were two planned primary comparisons in the trial, P values less than 0.025 were considered to be significant. O’Brien-Fleming statistical stopping guidelines were used, with one interim analysis for efficacy performed midway through the trial. For the animals
study, all the data are given as mean±s.e.m. Comparisons among different time points after BBR administration were assessed by mixed effect linear model, and Bonferroni correction was used for pairwise comparisons. A p-value<0.05 was considered statistically significant.

**Results**

**Study subjects**

A total of more than 313 subjects were initially enrolled for the study between March 2008 and April 2011. After clinical assessment, total 184 subjects were identified to participate the trial, of which 62 were assigned to receive LSI alone, 60 for LSI plus pioglitazone, and 62 for LSI plus BBR at randomization (Fig 1). The three groups were well matched in respect to demographic profiles, HFC and other baseline characteristics (Table 1). At the end of the trial, 53, 47 and 55 patients completed their follow-up visits, respectively (Fig 1). Compliance with the lifestyle intervention and study medications was over 90% in all groups (S1 Table).

**Hepatic fat content and liver enzymes**

After treatment, HFC decreased by 57.2% in the LSI plus BBR group (P<0.001) and by 36.4% in the LSI group (P<0.001). Treatment with LSI plus BBR caused more reduction of HFC as compared to that with LSI alone (p = 0.008, Fig 2). Moreover, the effect of BBR on HFC was no smaller than that of PGZ (15mg per day) (p = 0.054) [23]. Liver enzymes were also reduced in all groups after treatment, and the reduction of ALT and AST showed no significant difference between the LSI plus BBR and LSI plus PGZ groups at the 16th week (p = 0.855 and p = 0.632, respectively) (Table 2).

**Responses in energy metabolism**

In comparison with LSI alone, BBR exhibited extra decreases in body weight [-4.29(-5.04 -- 3.54)kg vs -1.99(-2.76 -- 1.23)kg, p<0.001], BMI [-1.51(-1.79 -- 1.25)kg/m² vs -0.72(-0.99 -- 0.44) kg/m², p<0.001], waist circumference [-4.84(-5.70 -- 3.97)cm vs -2.14(-3.03 -- 1.26)cm, p<0.001], HFC [-17.4(-20.8 -- 14.0)% vs -11.4(-14.8 -- 7.9)%], p = 0.008), 2h postload glucose [-2.19(-2.87 -- 1.51)mmol/L vs -1.05(-1.73 -- 0.37)mmol/L, p = 0.020], area under the OGTT curve [-6.14(-7.72 -- 4.55) vs -3.33(-4.93 -- 1.73)], p = 0.015], HOMA-IR [-1.06(-1.51 -- 0.61) vs -0.26(-0.72 -- 0.20), p = 0.014], serum cholesterol [-0.52(-0.71 -- 0.33)mmol/L vs -0.12(-0.31 -- 0.07)mmol/L, p = 0.004], APO-B [-0.12(-0.16 -- 0.08)g/L vs -0.05(-0.09 -- 0.01)g/L, p = 0.022] and triglycerides [-0.45(-0.68 -- 0.23)mmol/L vs -0.02(-0.24 -- 0.21)mmol/L, p = 0.007] (Table 2), showing clearly a significant benefit of BBR in metabolism. The blood glucose reduction in LSI plus BBR group occurred in the first 4 weeks of treatment and was sustained throughout the trial; a remarkable and time-dependent decrease of body weight was also observed in this group (Fig 2). As compared with the PGZ plus LSI group (the positive reference of the study), BBR plus LSI showed comparable effects in control of blood glucose and insulin sensitivity, whereas BBR has additional benefits in body weight and serum lipids (Table 2).

**Adverse Events**

A total of 61 drug-related adverse events (AEs) occurred in the participants. The most common AEs related to BBR were anorexia and upset stomach (30.95% of BBR-related AEs), diarrhea (26.19%) and constipation (14.29%), which could be well-tolerated within the initial two weeks of the study. No serious AEs, such as congestive heart failure, bone fractures, liver toxicity, were observed in the subjects. AEs occurred in PGZ group mainly included muscle pain,
Fig 1. CONSORT Flow Diagram. 184 subjects were assigned to receive lifestyle intervention alone (n = 62), lifestyle intervention plus pioglitazone (n = 60), and lifestyle intervention plus berberine (n = 62). At the end of therapy, 53, 47 and 55 subjects in the three groups completed the follow-up visit, respectively.

doi:10.1371/journal.pone.0134172.g001
fatigue, and cardiac symptoms (S2 Table). Owing to the AEs four patients discontinued the treatment with PGZ and one with BBR.

Table 1. Baseline Characteristics of the Study Subjects. The data were presented as the mean±SD, except for skewed variables, which were presented as the median with the interquartile range given in parentheses.

|                        | LSI                  | LSI plus PGZ           | LSI plus BBR           |
|------------------------|----------------------|------------------------|------------------------|
| Sex (M/F)              | 32/30                | 28/32                  | 38/24                  |
| Age (year)             | 50.64±10.69          | 53.52±8.62             | 50.72±9.76             |
| Weight (kg)            | 75.73±11.13          | 74.98±12.73            | 78.71±15.99            |
| BMI (kg/m2)            | 27.27±2.80           | 27.47±3.74             | 28.08±4.17             |
| Waist (cm)             | 93.34±7.81           | 93.09±8.91             | 95.88±10.98            |
| HFC (%)                | 29.5(21.0–44.5)      | 29.8(20.5–44.0)        | 30.2(22.3–43.1)        |
| Serum glucose (mmol/L) |                      |                        |                        |
| 0min                   | 6.09±0.96            | 6.28±1.08              | 6.37±0.92              |
| 30min                  | 10.61±1.91           | 11.14±1.88             | 11.10±1.54             |
| 60min                  | 12.36±2.93           | 12.87±3.01             | 12.98±2.59             |
| 120min                 | 9.97±3.17            | 11.18±3.54             | 11.11±2.98             |
| 180min                 | 6.23±2.42            | 6.78±2.85              | 6.92±2.50              |
| AUCg                   | 41.11±8.42           | 41.73±9.07             | 41.84±7.52             |
| HbA1c(%)               | 6.17±0.67            | 6.42±0.68              | 6.46±0.70              |
| Serum insulin (mU/mL)  |                      |                        |                        |
| 0min                   | 15.0(9.3–18.6)       | 13.7(10.0–18.2)        | 13.6(8.9–17.4)         |
| 30min                  | 66.0(38.2–89.4)      | 58.6(33.5–78.4)        | 52.0(36.2–68.4)        |
| 120min                 | 83.5(59.2–132.1)     | 88.8(58.9–136.6)       | 81.4(49.1–113.1)       |
| HOMA-IR                | 4.22±2.51            | 4.26±2.47              | 4.20±2.85              |
| HOMAα                  | 131.08±87.58         | 123.85±62.95           | 119.41±114.32          |
| ΔI30/ΔG30              | 13.51±11.65          | 10.94±8.99             | 10.06±8.79             |
| Lipid profile          |                      |                        |                        |
| TC (mmol/L)            | 4.94±0.71            | 5.38±0.89              | 5.29±0.91              |
| TG (mmol/L)            | 1.93±0.70            | 2.16±0.91              | 2.19±1.10              |
| HDL-c (mmol/L)         | 1.20±0.25            | 1.19±0.25              | 1.16±0.26              |
| LDL-c (mmol/L)         | 2.91±0.68            | 3.25±0.94              | 3.23±0.85              |
| APO-A (g/L)            | 1.27(1.11–1.39)      | 1.30(1.18–1.54)        | 1.25(1.08–1.44)        |
| APO-B (g/L)            | 1.00±0.19            | 1.08±0.20              | 1.07±0.21              |
| APO-E (mg/L)           | 46(39–52)            | 46(39–58)              | 49(40–57)              |
| LPα (mg/L)             | 135(90–219)          | 142(79–233)            | 105(54–183)            |
| Liver enzyme (U/L)     |                      |                        |                        |
| ALT                    | 34(20–54)            | 41(26–65)              | 33(23–49)              |
| AST                    | 25(20–30)            | 28(20–43)              | 24(19–32)              |
| γ-GT                   | 36(22–60)            | 40(27–58)              | 40(27–69)              |

doi:10.1371/journal.pone.0134172.t001

Serum and urine BBR concentrations

Eleven subjects from the LSI plus BBR group and eleven subjects from the LSI group were randomly selected for measurement of concentrations of serum and urine BBR and its metabolites before and after the 16-week intervention. At the end of 16-week treatment, the median levels of BBR in serum and urine were 6.99ng/ml and 79.2ng/ml, respectively, in the BBR-treated subjects (Table 3), whose baseline BBR concentrations were not detectable. In contrast, BBR was also not detectable before and after the intervention in LSI group. Urine analysis showed
that BBR was mainly excreted as its prototype with concentrations ranging from 4.49 ng/mL to 645.48 ng/mL. Although five BBR metabolites (M1, M2, M4, M12, M13) were detected in urine of the patients, all of the metabolites showed very low concentrations ranging from 0.01 to 10.15 ng/mL (approximately 70-fold lower than BBR). All the results indicated that the botanic compound BBR was well absorbed, metabolized and excreted mainly as its prototype from the urine.

BBR and Its Metabolites in liver after Oral Administration in Animal Model

It is noticeable that Subjects at the BBR plus LSI group lost significantly more hepatic fat content than the LSI group with the same degree of body weight loss (Fig 3), which indicated that the benefits of BBR on NAFLD and its related metabolic diseases might involve a direct action on hepatic energy metabolism. To further understand the therapeutic effects of BBR, we conducted experiments in a HFD-induced NAFLD animal model by treating rats with a single dose of BBR to exclude the interference of body weight change. As shown in Fig 4, BBR and its metabolites were distributed in the liver. Moreover, BBR concentrations in rat liver were 50
### Table 2. Changes of clinical and biochemical parameters after treatment.

All parameters were adjusted for age, BMI and the baseline parameter and represented as means (95%CI). P value after adjustment for age, BMI, baseline data.

|                       | LSI     | LSI plus PGZ | LSI plus BBR | P value (LSI plus BBR vs. LSI) | P value (LSI plus BBR vs. LSI plus PGZ) |
|-----------------------|---------|--------------|--------------|---------------------------------|----------------------------------------|
| Number                | 53      | 47           | 55           | -                               | -                                      |
| Weight (kg)           | -1.99(2.76--1.23) | -1.94(2.75--1.12) | -4.29(5.04--3.54) | <0.001                          | <0.001                                 |
| BMI (kg/m²)           | -0.72(-0.99--0.44) | -0.67(-0.97--0.38) | -1.51(-1.79--1.25) | <0.001                          | <0.001                                 |
| Waist (cm)            | -2.14(-3.03--1.26) | -2.60(-3.55--1.66) | -4.84(-5.70--3.97) | <0.001                          | 0.001                                  |
| HFC(%)                | -11.4(-14.8--7.9) | -12.1(-15.8--8.5) | -17.4(-20.8--14.0) | 0.008                           | 0.054                                  |
| Blood glucose (mmol/L)|                     |               |              |                                 |                                        |
| 0min                  | -0.15(-0.41--0.12) | -0.38(-0.66--0.10) | -0.47(-0.73--0.20) | 0.096                           | 0.658                                  |
| 30min                 | -0.63(-1.06--0.19) | -0.91(-1.38--0.45) | -1.03(-1.46--0.60) | 0.196                           | 0.725                                  |
| 60min                 | -1.23(-1.80--0.65) | -1.18(-1.79--0.57) | -1.86(-2.42--1.29) | 0.125                           | 0.112                                  |
| 120min                | -1.05(-1.73--0.37) | -2.44(-3.17--1.72) | -2.19(-2.87--1.51) | 0.020                           | 0.609                                  |
| 180min                | -0.90(-1.35--0.44) | -1.48(-1.97--1.00) | -1.57(-2.02--1.11) | 0.042                           | 0.799                                  |
| AUCg                  | -3.33(-4.93--1.73) | -5.51(-7.21--3.81) | -6.14(-7.72--4.55) | 0.015                           | 0.594                                  |
| HbA1c(%)              | -0.30(-0.43--0.16) | -0.44(-0.58--0.30) | -0.47(-0.60--0.33) | 0.078                           | 0.793                                  |
| Serum insulin (mU/mL) |                     |               |              |                                 |                                        |
| 0min                  | -0.85(-2.43--0.72) | -1.66(-3.35--0.02) | -1.59(-3.14--0.03) | 0.515                           | 0.949                                  |
| 30min                 | -3.10(-11.54--5.35) | 1.24(-7.73--10.22) | 6.93(-1.35--15.20) | 0.098                           | 0.362                                  |
| 120min                | 4.5(-10.9--19.9)  | -15.4(-32.0--1.1) | -13.6(-28.9--1.7) | 0.102                           | 0.874                                  |
| HOMA-IR               | -0.26(-0.72--0.20) | -0.69(-1.18--0.20) | -1.06(-1.51--0.61) | 0.014                           | 0.298                                  |
| Lipid profile         |                     |               |              |                                 |                                        |
| TC(mmol/L)            | -0.12(-0.31--0.07) | -0.11(-0.31--0.10) | -0.52(-0.71--0.33) | 0.004                           | 0.004                                  |
| TG(mmol/L)            | -0.02(-0.24--0.21) | -0.12(-0.36--0.12) | -0.45(-0.68--0.23) | 0.007                           | 0.050                                  |
| HDL-c(mmol/L)         | 0.005(-0.034--0.044) | 0.065(0.023--0.107) | 0.010(-0.029--0.049) | 0.861                           | 0.061                                  |
| LDL-c(mmol/L)         | -0.14(-0.32--0.04) | -0.05(-0.25--0.14) | -0.24(-0.42--0.07) | 0.442                           | 0.154                                  |
| APO-A(g/L)            | -0.01(-0.07--0.05) | -0.00(-0.06--0.07) | -0.09(-0.15--0.03) | 0.055                           | 0.036                                  |
| APO-B(g/L)            | -0.05(-0.09--0.01) | -0.05(-0.09--0.00) | -0.12(-0.16--0.08) | 0.022                           | 0.023                                  |
| APO-E(mg/L)           | -7.0(-10.7--3.2)  | -8.9(-13.0--4.8)  | -10.9(-14.6--7.2)  | 0.143                           | 0.476                                  |
| LP(a)(mg/L)           | 4.53(-22.3--31.3) | 17.8(-11.2--46.9) | 23.6(-2.9--50.1)  | 0.319                           | 0.774                                  |
| Liver enzyme (U/L)    |                     |               |              |                                 |                                        |
| ALT                   | -14.1(-18.0--10.2) | -20.5(-24.8--16.2) | -21.0(-24.9--17.1) | 0.015                           | 0.855                                  |
| AST                   | -6.5(-8.2--4.8)   | -8.3(-10.2--6.4)  | -8.9(-10.7--7.2)  | 0.050                           | 0.632                                  |
| γ-GT                  | -8.4(-13.9--3.0)  | -14.3(-20.2--8.5) | -11.7(-17.1--6.3) | 0.403                           | 0.517                                  |

doi:10.1371/journal.pone.0134172.t002

### Table 3. Contents of BBR and its metabolites in human blood and urine.

| Compound | M.W (m/z) | Concentration (ng/mL) [Median (P_{25}--P_{75})] |
|----------|-----------|-----------------------------------------------|
| Serum    | BBR       | 336                                           | 6.99(4.65--9.82) |
| Urine    | BBR       | 336                                           | 79.16(3.37--326.16) |
| M1       | 322       | 0.56(0--3.01)                                 |
| M2       | 322       | 0.66(0--2.04)                                 |
| M4       | 338       | 0.03(0--0.08)                                 |
| M12      | 498       | 0(0--0.02)                                    |
| M13      | 402       | 0.17(0--0.57)                                 |

doi:10.1371/journal.pone.0134172.t003
times higher than that in the plasma (Table 4). The first peak of BBR (886.80 ±174.55ng/g) in the liver occurred at 4 hrs after oral administration of the drug and second peak at 24 hrs (724.44±51.89 ng/g), followed by a significant decline. BBR metabolites exhibited a similar time-concentration relationship to that of BBR.

**Effects of BBR on Hepatic Gene Expression**

Having shown a preferable distribution of BBR in the liver, we further determine the effect of BBR on hepatic glucose and lipid metabolism. One single dose of BBR treatment significantly increased serum triglyceride and reduced serum ALT and AST concentration within 48 hours, without change of body weight (Table 5). As shown in Fig 5A–5E, the relative mRNA of CPT-1α, MTTP and GCK were significantly up-regulated (P<0.05) in the liver of HFD-fed rat orally treated with a single dose of BBR. Western blot analysis showed a result consistent with that in real-time PCR (Fig 5F). The expression of CPT-1, MTTP and GCK reached the peak at 24 hrs after oral administration of BBR, parallel with a second peak of liver BBR concentration (Table 4). These data suggest a pleiotropic effect of BBR on the energy metabolism network in the liver, which may account for its direct therapeutic effect on NAFLD.
Discussion

The beneficial effects of BBR on glucose and lipid metabolism have been fully demonstrated. However, the mechanism underlying its therapeutic effect is still unclear. In our current study, we found that BBR was absorbable and mainly located in the liver (50 times higher than that in the plasma) after oral administration. With its preferential distribution in liver, BBR profoundly ameliorated liver steatosis in the NAFLD patients from our randomized clinical trial and directly regulated the expression of hepatic genes related to glucose and lipid-metabolism.

Table 4. Concentration of BBR in HFD rat liver and plasma.

| Time point | Liver Concentration (ng/ml) | Plasma Concentration (ng/ml) |
|------------|-----------------------------|-------------------------------|
| 0h         | 0                           | 0                             |
| 4h         | 782.37(362.51–1132.86)      | 0.78(0.00–2.74)               |
| 8h         | 472.11(295.77–660.08)       | 0.30(0.00–1.39)               |
| 12h        | 576.76(380.19–769.51)       | 6.77(0.40–31.40)              |
| 24h        | 734.46(486.33–921.22)       | 3.24(1.05–26.56)              |
| 48h        | 51.71(24.35–109.61)         | 4.14(3.75–5.32)               |

doi:10.1371/journal.pone.0134172.t004
To the best of our knowledge, our current study is the first human study focusing on the BBR’s therapeutic effects on NAFLD, and we also measure its concentration in serum, urine and liver as well as hepatic gene expression related to glucose and lipid metabolism after BBR treatment.

In the present study, BBR treatment for 16-weeks in combination with LSI significantly reduced hepatic fat content in NAFLD patients, paralleled with a global metabolic benefit as reflected in reducing body weight, and improving glucose and lipid profiles. In comparison with LSI alone, BBR exhibited extra benefits in the improvement of body weight, HFC, HOMA-IR and lipid levels. Even compared with PGZ (15 mg/day) [24], BBR had not only a similar reduction of blood glucose and HFC, but also beneficial effects on body weight. Although gastro-enteric AEs related to BBR were observed, they were mild and tolerable. BBR was absorbable after oral administration in our study patients and studies on rat models showed that BBR was located favorably in the liver and could alter hepatic metabolism-related gene expression.

Patients in the berberine group lost significantly more liver fat content, and showed more reductions in blood glucose, triglycerides and cholesterol than the LSI group, which was concordant with those in previous studies [8,9,13]. A remarkable decrease in body weight was also observed in participants of BBR group. Several studies reported that the BBR had an extreme low bioavailability of less than 1% in BBR-treated animals [25,26], therefore it was believed that BBR was not absorbable in human gastrointestinal tract and its beneficial effects on hepatic fat, insulin resistance as well as glucose and lipid metabolism mainly depended on its effect on gut microbiota[27], and all of the hepatic fat and metabolic improvements might depended on significant weight loss after BBR treatment. However, our current study found that subjects at the BBR plus LSI group lost significantly more liver fat content than the LSI group with the same degree of body weight reduction (Fig 3), which indicated that the improvement of liver steatosis after BBR treatment not only related to the significant body weight reduction. Therefore, we further analyzed the serum and urine BBR concentrations using the accurate LC-MS/MS analysis in our human study, and found that BBR was absorbed by oral administration, metabolized in the liver and excreted in urine mainly in its prototype using LC-MS/MS analysis, which suggested its direct effect on the liver.

To further explore the possible mechanism underlying BBR’s direct effect on NAFLD in human beings, we measured the distribution of BBR (and its metabolites) after BBR treatment in the HFD-induced animal model of NAFLD. As compared to its concentration in blood, BBR (and its metabolites) favored to locate in liver with a concentration 50 times higher than that in the plasma (Table 4). In fact the phenomena of liver-selective enrichment have been reported in BBR[20,28] and other botanic medicinal alkaloids[29].

Table 5. Phenotype of HFD-induced NAFLD rats after treating with single-dose BBR.

|                          | HFD-0h       | HFD-4h       | HFD-8h       | HFD-12h      | HFD-24h      | HFD-48h      | P for trend |
|--------------------------|--------------|--------------|--------------|--------------|--------------|--------------|------------|
| **Body weight (g)**      | 428.5±20.79  | 391.0±20.15  | 400.0±39.59  | 426.7±21.96  | 429.0±35.38  | 402.5±31.50  | 0.103      |
| **Liver weight (g)**     | 13.9±0.90    | 12.4±1.26    | 13.1±1.50    | 13.9±1.28    | 14.4±2.46    | 12.0±1.79    | 0.096      |
| **Brown fat (g)**        | 0.47±0.14    | 0.31±0.07    | 0.39±0.16    | 0.41±0.10    | 0.42±0.08    | 0.37±0.06    | 0.227      |
| **Epididymal fat (g)**   | 6.3±3.11     | 4.4±0.67     | 5.3±1.73     | 5.7±1.75     | 6.0±1.78     | 5.4±1.51     | 0.587      |
| **TC**                   | 1.6±0.34     | 1.7±0.24     | 1.8±0.46     | 1.6±0.51     | 2.0±0.36     | 2.1±0.32     | 0.177      |
| **TG**                   | 0.36±0.08    | 0.70±0.23    | 0.49±0.19    | 0.34±0.09    | 0.70±0.28    | 0.83±0.17    | <0.001     |
| **HDL-c**                | 0.90±0.19    | 0.93±0.19    | 1.09±0.28    | 0.97±0.31    | 1.09±0.21    | 1.08±0.19    | 0.551      |
| **ALT**                  | 92.67±52.79  | 47.17±5.91   | 39.33±7.23   | 46.17±6.59   | 79.17±18.71  | 75.67±17.0   | 0.002      |
| **AST**                  | 376.67±197.57 | 143.83±13.18 | 126.17±24.26 | 139.17±24.98 | 270.33±41.00 | 297.83±89.60 | <0.001     |

doi:10.1371/journal.pone.0134172.t005

Effects of Berberine on NAFLD

PLOS ONE | DOI:10.1371/journal.pone.0134172 August 7, 2015 12 / 16
Fig 5. A-E) Altered expression of genes closely related to glucose and lipid metabolism in liver of SD rats. The samples were examined within 48h after single-dosing of BBR in oral route. Real-time quantitative PCR was used to detect the liver A) MTTP, B) CPT-1α, C) GCK, D) LDLR and E) LPK mRNA expression at different time courses. F) Quantification of the MTTP, CPT-1, C) GCK, D) LDLR and E) LPK mRNAs were examined within 48h after single-dosing of BBR in oral route. iMTTP, microsomal triglyceride transfer protein; CPT-1α, carnitine palmitoyltransferase-1α; GCK, glucokinase; LDLR, low density lipoprotein receptor; LPK, liver pyruvate kinase.

doi:10.1371/journal.pone.0134172.g005
However, the liver-selective enrichment of BBR is possibly the hepatic first-pass effect, which does not mean a bioactivity on glucose and lipid metabolism, so we examined hepatic expression of a group of energy metabolism related genes MTTP, CPT-1a and GCK at 0, 4, 8, 12, 24 and 48h after oral administration of a single dose of BBR. The expression of these genes in liver was significantly up-regulated after BBR treatment, with no significant change of body weight at each time point, indicating a direct effect of BBR on hepatic expression of metabolism related genes. MTTP was for the assembly and secretion of apoB-containing lipoproteins (VLDL and LDL)[15], CPT-1a was a part of the outer membrane fatty acid transfer complex and catalyzed the primary regulated step in overall mitochondrial fatty acid oxidation[30]. The up-regulation of these genes after BBR treatment might promote the export and β-oxidation of liver fat, and partially account for its therapeutic effect in improving liver steatosis. GCK was for regulation of glucose metabolism rate[31], and also increased after BBR treatment. It has been reported that BBR could decrease insulin resistance by activating liver AMPK [32], and hepatic GCK up-regulation might relate to the activation of hepatic AMPK pathway[33]. Therefore, BBR may have multiple effects on liver genes associated with lipid or glucose metabolism. It is likely that the significant anti-NAFLD effect of BBR is related to its favorite location in liver and its direct effects on multiple hepatic genes that links to energy metabolism.

The limitation of this study is that none of these patients was examined by liver biopsy because of the ethics concern, and the effects of BBR on human hepatic histological inflammation, fibrosis as well as the genes related to energy metabolism need to be further studied.

Conclusion

Oral administration of BBR significantly reduced HFC, body weight, and improved metabolic profile for lipid and glucose in patients with NAFLD. The therapeutic efficacy of BBR on NAFLD and its related glucose and lipid metabolism related to its favorite location in liver and its direct effects on multiple hepatic genes that links to energy metabolism. Therefore, BBR is a promising agent to treat NAFLD, as well as their related metabolic diseases.

Supporting Information

S1 ARRIVE Checklist. NC3Rs ARRIVE Guidelines.
(PDF)

S1 CONSORT Checklist. CONSORT Checklist.
(DOC)

S1 Fig. Design schematic of the clinical trial.
(TIF)

S1 Protocol. Trial Protocol (English).
(DOCX)

S2 Protocol. Trial Protocol (Chinese).
(DOC)

S1 Table. Compliance of lifestyle intervention and medication in the three groups.
(DOCX)

S2 Table. Drug-related adverse events in the clinical trial.
(DOCX)
S1 Text. Detailed description of the methods of real-time quantitative polymerase-chain-reaction (PCR) analysis, Western blot analysis, and measurement of BBR and its metabolites in the liver tissue using a shimadzu triple-quadruple MS (LC–MS/MS 8040; Shimadzu Corporation, Kyoto Japan) in animal model.

Acknowledgments
The authors thank Professor Pu XIA (Zhongshan Hospital, Fudan University) for critical reading of the manuscript.

Author Contributions
Conceived and designed the experiments: XG JJ WJ HY. Performed the experiments: HY MX YW XC XY SR MZ YT RF JL. Analyzed the data: WD MX YW. Contributed reagents/materi- als/analysis tools: XY SR MZ RF. Wrote the paper: XG JJ MX HY.

References
1. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008; 48 (Suppl 1): S104–12. doi: 10.1016/j.jhep.2008.01.009 PMID: 18304679
2. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43 (2 Suppl 1):S99–S112. PMID: 16447287
3. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013; 10:330–44. doi: 10.1038/nrgastro.2013.41 PMID: 23507799
4. Adams LA, Waters OR, Knuman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol. 2009; 104:861–67. doi: 10.1038/ajg.2009.67 PMID: 19293782
5. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic-steatohepatitis. N Engl J Med. 2006; 355:2297–307. PMID: 17135584
6. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic-steatohepatitis. N Engl J Med; 362:1675–85. doi: 10.1056/NEJMoa0907929 PMID: 20427778
7. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-con- trolled trial of pioglitazone in nondiabetic subjects with nonalcoholic-steatohepatitis. Gastroenterology 2008; 135:1176–84. doi: 10.1053/j.gastro.2008.06.047 PMID: 18718471
8. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism.2008; 57:712–7. doi: 10.1016/j.metabol.2008.01.013 PMID: 18442638
9. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004; 10: 1344–51. PMID: 15531889
10. Cameron J, Ranheim T, Kulseth MA, Leren TP, Berge KE. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis. 2008; 201: 266–73. doi: 10.1016/j.atherosclerosis.2008.02.004 PMID: 18359829
11. Lu SS, Yu YL, Zhu HJ, Liu XD, Liu L, Liu YW, et al. Berberine promotes glucagon-like peptide-1 (7–36) amide secretion in streptozotocin-induced diabetic rats. Journal of Endocrinology. 2009; 200:159–65. doi: 10.1677/JOE-08-0419 PMID: 18999945
12. Kong WJ, Zhang H, Song DQ, Xue R, Zhao W, Wei J, et al. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism: Clinical and Experimental. 2009; 58:109–19.
13. Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008; 93:2559–65. doi: 10.1210/jc.2007-2404 PMID: 18397984
14. Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature. 2014; 510:84–91. doi: 10.1038/nature13478 PMID: 24899308
15. Chang X, Yan H, Fei J, Jiang M, Zhu H, Lu D, et al. Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats. J Lipid Res. 2010; 51: 2504–15.

16. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005; 288:E462–8. PMID: 15339742

17. Farrell GC, Chitturi S, Lau GK, Sollano JD. Asia-Pacific Working Party on NAFLD. Guidelines for the assessment and management of nonalcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol 2007; 22:775–7. PMID: 17565629

18. Cho E. Berberini hydrochloride. in Pharmacopoeia of the People's Republic of China 2, 1990:437–439.

19. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, exenatide. Int J Obes (Lond). 2012; 36:843–54.

20. Tan XS, Ma JY, Feng R, Ma C, Chen WJ, Sun YP, et al. Tissue distribution of berberine and its metabolites after oral administration in rats. PLoS One. 2013;31; 8:e77969. doi: 10.1371/journal.pone.0077969 PMID: 24205048

21. Bian H, Yan H, Zeng M, Rao S, Yao X, Zhou J, et al. Increased liver fat content and unfavorable glucose profiles in subjects without diabetes. Diabetes Technol. Ther. 2011; 13: 149–55. doi: 10.1089/dia.2010.0101 PMID: 21284482

22. Ma JY, Feng R, Tan XS, Ma C, Shou JW, Fu J, et al. Excretion of berberine and its metabolites in oral administration in rats. J Pharm Sci. 2013; 102:4181–92. doi: 10.1002/jps.23718 PMID: 24006193

23. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006; 355:2297–307. PMID: 17135584

24. Takihata M, Nakamura A, Tajima K, Inazumi T, Komatsu Y, Tamura H, et al. Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial. Diabetes Obes Metab. 2013; 15:455–62. doi: 10.1111/dom.12055 PMID: 23279373

25. Chen W, Miao YQ, Fan DJ, Yang SS, Lin X, Meng LK, et al. Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats. Aaps Pharmscitech 2011; 12: 705–11. doi: 10.1208/s12249-011-9632-z PMID: 21637946

26. Hua W, Ding L, Chen Y, Gong B, He J, Xu G. Determination of berberine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry. J Pharm Biomed Anal. 2007; 44:931–7. PMID: 17531424

27. Liu YT, Hao HP, Xie HG, Lai L, Wang Q, Liu CX, et al. Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug Metab Dispos. 2010; 38:1779–84. doi: 10.1124/dmd.110.033936 PMID: 20634337

28. Liu J, Huang X, Xue M, Jiang Z, Zhang L, Ma S. Tissue distribution of 4 alkaloids of Compound Matrine Injection in rats. Pharmacology and Clinics of Chinese Materia Medica. 2011; 27: 74–8.

29. Reiling E, van Riet E, Groenewoud MJ, Welschen LM, van Hove EC, Nijpels G, et al. Combined effects of single-nucleotide polymorphisms in GCK, GCKR, G6P2 and MTNR1B on fasting plasma glucose and type 2 diabetes risk. Diabetologia. 2009; 52:1866–70. doi: 10.1007/s00125-009-1413-9 PMID: 19533084

30. Li H, Wang Y, Mao Y, Hu R, Xu W, Lei Z, et al. Long term liver specific glucokinase gene defect induced diabetic cardiomyopathy by up regulating NADPH oxidase and down regulating insulin receptor and p-AMPK. Cardiovasc Diabetol. 2014; 13:24. doi: 10.1186/1475-2840-13-24 PMID: 24447392